580 related articles for article (PubMed ID: 18945962)
1. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
[TBL] [Abstract][Full Text] [Related]
2. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
4. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
5. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
6. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.
Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Marsh SG; Spellman S; Haagenson MD; Saeturn K; Ladner M; Trachtenberg E; Parham P; Miller JS
J Immunol; 2014 May; 192(10):4592-600. PubMed ID: 24748496
[TBL] [Abstract][Full Text] [Related]
7. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Trachtenberg E; Haagenson MD; Spellman SR; Ladner M; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1602-1607. PubMed ID: 27220262
[TBL] [Abstract][Full Text] [Related]
8. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation.
Hosokai R; Masuko M; Shibasaki Y; Saitoh A; Furukawa T; Imai C
Biol Blood Marrow Transplant; 2017 Apr; 23(4):606-611. PubMed ID: 28042021
[TBL] [Abstract][Full Text] [Related]
9. The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.
Khanuntong S; Kuptawintu P; Upaisilpsathaporn K; Poolchareon A; Bunworasate U; Hirankarn N
HLA; 2016 Jun; 87(6):422-31. PubMed ID: 27273744
[TBL] [Abstract][Full Text] [Related]
10. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
[TBL] [Abstract][Full Text] [Related]
11. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.
Stringaris K; Adams S; Uribe M; Eniafe R; Wu CO; Savani BN; Barrett AJ
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1257-64. PubMed ID: 20302958
[TBL] [Abstract][Full Text] [Related]
12. Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
Krieger E; Qayyum R; Toor A
Br J Haematol; 2024 May; 204(5):1935-1943. PubMed ID: 38442905
[TBL] [Abstract][Full Text] [Related]
13. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
[TBL] [Abstract][Full Text] [Related]
14. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.
Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Le CT; Marsh SG; Geraghty D; Spellman S; Haagenson MD; Ladner M; Trachtenberg E; Parham P; Miller JS
Blood; 2010 Oct; 116(14):2411-9. PubMed ID: 20581313
[TBL] [Abstract][Full Text] [Related]
15. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
[TBL] [Abstract][Full Text] [Related]
16. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
17. The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.
An K; Li B; Luo C; Wang J; Luo C; Chen J
Pediatr Transplant; 2020 Sep; 24(6):e13728. PubMed ID: 32594584
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.
Davies SM; Iannone R; Alonzo TA; Wang YC; Gerbing R; Soni S; Kolb EA; Meshinchi S; Orchard PJ; Burns LJ; Shenoy S; Leung W
Biol Blood Marrow Transplant; 2020 Apr; 26(4):712-717. PubMed ID: 31870931
[TBL] [Abstract][Full Text] [Related]
19. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
[TBL] [Abstract][Full Text] [Related]
20. The effect of killer cell immunoglobulin-like receptor genotype on outcome of hematopoietic stem cell transplantation from matched sibling.
Elfishawi SM; Mossallam GI; El-Fattah RA; El-Haddad A; Kamel AM
Hum Immunol; 2017 Nov; 78(11-12):684-691. PubMed ID: 28993188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
